

**For information contact:**

*Corporate Contacts*

Katrine Bosley  
Vice President Business Development  
Adnexus Therapeutics, Inc.  
781-891-3745  
pr@adnexustx.com

*Media Contacts*

Courtney Harris  
Feinstein Kean Healthcare  
617-761-6744  
Courtney.Harris@fkhealth.com

**ADNEXUS THERAPEUTICS TO PRESENT AT THOMAS WEISEL PARTNERS  
HEALTHCARE CONFERENCE**

**Waltham, MA, September 5, 2006** - Adnexus Therapeutics™, Inc. today announced its presentation at the Thomas Weisel Partners Healthcare Conference at the Four Seasons Hotel in Boston on Wednesday, September 6, 2006 at 11:30 a.m. Eastern Time.

John Mendlein, Ph.D., CEO of Adnexus Therapeutics, will provide an overview of the company and discuss its technology and therapeutic programs, which are based on the Adnectin™ targeted protein therapeutic class.

**About the New AdNectin Product Class and the PROfusion System**

Adnectins are an emerging protein therapeutic class that can be designed to address a broad range of diseases. They are based on human fibronectin, an extracellular protein that is naturally abundant in human serum. The intrinsic properties of an Adnectin align with the properties needed to make a successful drug, including high potency, specificity, stability, favorable half life, and high yield production. These and other important characteristics are predictable for the Adnectin product class, which greatly accelerates Adnectin drug discovery and development.

Adnectins are designed using the PROfusion™ System, Adnexus' patented protein design engine, to achieve high potency and specificity for a therapeutic target while simultaneously selecting for ideal pharmaceutical product characteristics. PROfusion enables Adnexus to screen over 1 trillion unique Adnectins for each target to "redirect" a naturally occurring human fibronectin to act as a protein therapeutic.

Adnexus is the exclusive developer of Adnectins. Adnexus solely owns the Adnectin patent estate that controls issued and pending patent properties to fundamental Adnectin forms. In addition, Adnexus exclusively controls its patented PROfusion System. Adnexus has over 100 issued and pending patent properties relating to Adnectins and PROfusion.

**About Adnexus Therapeutics**

Adnexus Therapeutics is focused on generating vital medicines through the discovery, development, and commercialization of its broadly applicable new therapeutic class, Adnectins. Adnexus lead product candidate, CT-322, is in Phase 1 clinical development. The company also has a pipeline of other Adnectin products in preclinical research across multiple therapeutic areas. Adnectins are designed and optimized using PROfusion, the company's patented protein design engine that uniquely enables rapid optimization of protein therapeutics. The company is funded by four leading venture capital firms: Atlas Venture, Flagship Ventures, Polaris Venture Partners, and Venrock Associates.

*This news release contains certain forward-looking statements that involve risks and uncertainties. Such statements are only predictions and the company's actual results may differ materially from those anticipated in these forward-looking statements. Factors that may cause such differences include the timing of clinical trials, the risk that products that appeared promising in early research and clinical trials do not demonstrate safety or efficacy in clinical trials and the risk that the company will not obtain approval to market its products.*

*Adnectin™, Adnexus Therapeutics™ and PROfusion™ are trademarks of Adnexus Therapeutics™, Inc. Adnexus Therapeutics<sup>SM</sup> is a service mark of Adnexus Therapeutics™.*

For more information, please visit [www.adnexustx.com](http://www.adnexustx.com).